JD Health's Revenue Growth Likely Slowed in First Quarter — Market Talk

About this update from Jd Health International, Inc.

JD Health's revenue growth likely slowed in the first quarter, though demand should stay resilient, Nomura says in a note. The brokerage estimates revenue rose 17% on year in the first quarter, down from 27% growth in the fourth quarter, mainly because demand related to the peak of the flu season came earlier than usual. Nomura says pharmaceutical sales should remain supported by growth in prescription volumes and rising online penetration. Nomura maintains a buy rating and its target price of HK$80.00. Shares are HK$47.14. ([email protected])

View stock analysis, news, and events for Jd Health International, Inc.